Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

Not Applicable

Recruiting

• Conditions: Pancreatic Neoplasm; Pancreatic Cancer; Liver Metastases
• Interventions: Diagnostic Test: Preoperative MRI

• Registration Number: NCT05428358
• Lead Sponsor: University of Aarhus

Brief Summary

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

Detailed Description

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.

Study Timeline

• Study First Submitted: 2022-06-16
• Study First Submitted QC: 2022-06-16
• Study First Posted: 2022-06-23
• Study Start: 2022-08-30
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-26
• Last Update Posted: 2025-03-27
• Primary Completion: 2027-12-01
• Study Completion: 2028-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Preoperative MRI	Preoperative MRI	MRI before surgery.

Primary Outcome Measures

Name	Time	Method
Change in treatment strategy	1 week	Change in treatment strategy from intended curative resection to other treatment based on MRI scan

Secondary Outcome Measures

Name	Time	Method
Surgery	1 month	Proportion of patients who made it to surgery/exploration
Intraoperatively detected liver metastases	1 month	Proportion of patients with intraoperatively detected liver metastases not seen on either CT or MRI.
Liver metastases	1 week	Proportion of patients who had liver metastases detected on MRI
Overall survival (1-year)	1 year	1-year overall survival.
Resection	1 month	Proportion of patients in each arm who had a pancreatic resection performed
Overall survival (3-year)	3 years	3-year overall survival.
Recurrence-free survival	3 years	Recurrence-free survival according to final treatment strategy.
Healthcare costs	3 years	Healthcare costs in patients with change of treatment.

Trial Locations

Locations (4)

Aalborg University Hospital; 🇩🇰 Aalborg, Denmark

Aarhus University Hospital; 🇩🇰 Aarhus, Denmark

Odense University Hospital; 🇩🇰 Odense, Denmark

Rigshospitalet; 🇩🇰 Copenhagen, Denmark